| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
(+)-Nortrachelogenin targets HIV protease, apoptosis pathways, and PI3K. It exhibits acetylcholinesterase (AChE) inhibitory activity. The compound is a pharmacological ligand from Wikstroemia indica with anti-leukemic bioactivity. It shows moderate activity against HIV-1 in vitro.
|
|---|---|
| ln Vitro |
In MDA-MB-231 cells, wiskstromol inhibits the PI3K/Akt pathway to cause apoptosis and reduce migration[2].
(+)-Nortrachelogenin shows anti-leukemic activity and has been found to be active against P-388 lymphocytic leukemia growth. It exhibits moderate activity against HIV-1 in vitro. The compound shows acetylcholinesterase (AChE) inhibitory activity. It induces apoptosis and suppresses cancer cell migration at relatively low concentrations. |
| ln Vivo |
(+)-Nortrachelogenin has been found to be active against P-388 lymphocytic leukemia growth implanted in mice. It showed effects on the central nervous system producing depression in rabbits. These in vivo studies demonstrate its biological activity in animal models.
|
| Enzyme Assay |
In vitro enzyme assays measure acetylcholinesterase (AChE) inhibition. Anti-HIV-1 activity is assessed through viral replication assays. Antileukemic activity is evaluated using cell viability assays in P-388 lymphocytic leukemia cells.
|
| Cell Assay |
Cell-based assays use P-388 lymphocytic leukemia cells to measure antileukemic activity. Apoptosis induction and cancer cell migration inhibition are assessed. Anti-HIV-1 activity is evaluated in infected cell cultures.
|
| Animal Protocol |
In vivo efficacy is evaluated in mice implanted with P-388 lymphocytic leukemia. The compound's ability to inhibit tumor growth is assessed. CNS effects are studied in rabbits. Further studies are needed to fully characterize its in vivo pharmacology.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for (+)-nortrachelogenin are limited. As a natural lignan, its absorption, distribution, metabolism, and excretion properties have not been extensively characterized. Further pharmacokinetic studies are needed to determine its bioavailability and metabolic stability.
|
| Toxicity/Toxicokinetics |
Toxicological data for (+)-nortrachelogenin are limited. As a natural product, its safety profile has not been fully established. Standard laboratory safety precautions should be followed when handling this compound. Further toxicity studies are needed for comprehensive safety assessment.
|
| References | |
| Additional Infomation |
(+)-norcalicinoside has been reported in Carissa Karandas, Daphne Accutilloba, and other organisms with available data.
(+)-Nortrachelogenin (Wikstromol) is a naturally occurring lignan with anti-leukemic, anti-HIV-1, and AChE inhibitory activities. It induces apoptosis and suppresses cancer cell migration. The compound is a pharmacological ligand from Wikstroemia indica and has been active against P-388 lymphocytic leukemia in mice. It is a valuable research tool for studying cancer, infectious diseases, and neuroscience. |
| Molecular Formula |
C20H22O7
|
|---|---|
| Molecular Weight |
374.38
|
| Exact Mass |
374.136
|
| CAS # |
61521-74-2
|
| Related CAS # |
Nortrachelogenin;34444-37-6
|
| PubChem CID |
479756
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
609.2±50.0 °C at 760 mmHg
|
| Flash Point |
217.3±23.6 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.630
|
| LogP |
0.92
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
513
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
COC1=C(C=CC(=C1)C[C@@H]2COC(=O)[C@]2(CC3=CC(=C(C=C3)O)OC)O)O
|
| InChi Key |
ZITBJWXLODLDRH-JLTOFOAXSA-N
|
| InChi Code |
InChI=1S/C20H22O7/c1-25-17-8-12(3-5-15(17)21)7-14-11-27-19(23)20(14,24)10-13-4-6-16(22)18(9-13)26-2/h3-6,8-9,14,21-22,24H,7,10-11H2,1-2H3/t14-,20-/m1/s1
|
| Chemical Name |
(3R,4R)-3-hydroxy-3,4-bis[(4-hydroxy-3-methoxyphenyl)methyl]oxolan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6711 mL | 13.3554 mL | 26.7108 mL | |
| 5 mM | 0.5342 mL | 2.6711 mL | 5.3422 mL | |
| 10 mM | 0.2671 mL | 1.3355 mL | 2.6711 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
